acamprosate controlled-release (SNC-102) / Synchroneuron - LARVOL DELTA

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Synchroneuron Inc.; N=102 ➔ 0

Enrollment change • Movement Disorders

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome (clinicaltrials.gov) - P2a; N=0; Withdrawn; Sponsor: Synchroneuron Inc.; Phase classification: P2 ➔ P2a; N=16 ➔ 0

Enrollment change • Phase classification • Movement Disorders • Tourette Syndrome